Osteoporosis, a growing epidemic among women in North America, Europe, and Japan, is a painful, costly disease that has presented a treatment challenge to healthcare professionals. Until recently, therapies have focused on agents that slow bone resorption, and have had only limited success at increasing bone mass.
However, exciting new developments are on the verge of changing the treatment of this debilitating disorder. Two anabolic agents, the parathyroid hormone (PTH) and the fluoride ion, show tremendous promise as tools for building and retaining bone - with no adverse side effects. Anabolic Treatments for Osteoporosis is a comprehensive account of the latest studies that have been carried out on these two agents, and a thorough assessment of their prospects as osteoporosis therapeutics. This unique book combines basic science and up-to-date clinical data to present a complete picture of this breakthrough in the treatment of a globally significant health issue.
Osteoporoses: Their Nature and Therapeutic Targets, H.M. Frost
Osteoporosis - Mechanisms and Models, L. Mosekilde
PTH: Skeletal Effects in the Ovariectomized Rat Model for Postmenopausal Bone Loss, T.J. Wronski and M. Li
Parathyroid Hormone: The Clinical Experience and Prospects, A.B. Hodsman, L.J. Fraher, and P.H. Watson
Adenylyl Cyclase-Activating Anabolic Agents: Parathyroid Hormone and Prostaglandins E, J.F. Whitfield, P. Morley, R. Langille, and G. Willick
Bone Formation May Be Uncoupled from Resorption, as Demonstrated by a New Class of hPTHrP-(1-34) Analogues in Both Rapid and Slow Turnover Models of Osteopenia, B.H. Vickery, Z. Avnur, G.I. McRae, R. Waters, E. Hill, and J.L. Krstenansky
Commercial Exploitation of Parathyroid Hormone Therapy for the Treatment of Postmenopausal Osteoporosis, G. Marchand
The Insulin-Like Growth Factors: Potential Anabolic Agents for the Skeleton, A. Johansson and C.J. Rosen
Osteogenic Actions of Fluoride: Its Therapeutic Use for Established Osteoporosis, K.-H. W. Lau, K. Åkesson, C.R. Libanati, and D.J. Baylink